stockrow
Saturday 7 November 2026
Export EOCN’s income statement to Excel — free account
Eocene Ltd.
EOCN Healthcare Biotechnology
- EPS
- +43.3%
- Free cash flow
- −67.7%
Quarter to June 2026, against a year earlier
2.74
0.29
+11.84%
Follow EOCN
Alert me
Eocene Ltd. (EOCN) P/E ratio
Eocene Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2018 | 0.0× | — |
| Sep 2018 | 0.0× | — |
| Jun 2018 | 0.0× | — |
| Mar 2018 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| EOCN Eocene Ltd. | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| DCOY Decoy Therapeutics Inc compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)